Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Current Assets (2016 - 2025)

Haemonetics has reported Current Assets over the past 16 years, most recently at $943.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 6.18% year-over-year to $943.7 million; the TTM value through Dec 2025 reached $943.7 million, down 6.18%, while the annual FY2025 figure was $935.0 million, 21.6% up from the prior year.
  • Current Assets for Q4 2025 was $943.7 million at Haemonetics, up from $899.7 million in the prior quarter.
  • Over five years, Current Assets peaked at $1.0 billion in Q4 2024 and troughed at $684.4 million in Q3 2021.
  • A 5-year average of $813.8 million and a median of $769.3 million in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: fell 9.88% in 2021 and later soared 31.49% in 2024.
  • Year by year, Current Assets stood at $699.2 million in 2021, then grew by 1.01% to $706.3 million in 2022, then increased by 8.31% to $765.0 million in 2023, then surged by 31.49% to $1.0 billion in 2024, then fell by 6.18% to $943.7 million in 2025.
  • Business Quant data shows Current Assets for HAE at $943.7 million in Q4 2025, $899.7 million in Q3 2025, and $913.2 million in Q2 2025.